Soft-tissue sarcomas alter the biology of immune cells around tumors, promoting tumor development
Cedars-Sinai Medical Center researchers have found that cancerous tumors known as soft-tissue sarcomas release a protein that causes immune cells to change their behavior from tumor-attacking to tumor-promoting. The work, which was recently published in the peer-reviewed journal Cell Reports, may help treat soft-tissue sarcomas more effectively.
The study focused on the ecosystem of blood vessels and other cells that tumors attract in order to provide them with nutrients and support their survival.
“Tumors also recruit immune cells,” said Jlenia Guarnerio, Ph.D., a research scientist with Cedars-Sinai Cancer, assistant professor of Radiation Oncology and Biomedical Sciences, and senior author of the study. “These immune cells should be able to recognize and attack the tumor cells, but we found that the tumor cells secrete a protein that changes their biology, so instead of killing tumor cells they actually do the opposite.”
Soft-tissue sarcoma is a rare cancer that develops in muscle, fat, blood vessels, nerves, tendons, and joint lining. The American Cancer Society estimates that it kills over 5,000 Americans annually and that it most frequently affects the arms, legs, and abdomen.
Guarnerio and her colleagues discovered that the majority of these tumors contain an overabundance of immune cells termed myeloid cells in their microenvironment when comparing samples of various soft-tissue sarcomas from laboratory mice and people.
“It was striking that such a large percentage of the immune cells were myeloid cells, and we thought that since they obviously weren’t killing the tumor cells, they must be doing something to promote tumor growth,” said Stephen Shiao, MD, Ph.D., division director of the Division of Radiation Biology, co-leader of the Translational Oncology Program and a co-author of the study. “And indeed, our analysis of tumor samples showed that many of the myeloid cells had adopted a tumor-promoting function.”
To find out what was causing this change, investigators examined the proteins secreted by the tumor cells and the receptors on the surface of the myeloid cells—the elements cells use to communicate. “We examined the cross-talk between these two populations of cells,” Guarnerio said. “We found that the tumor cells expressed high levels of a protein called macrophage migration inhibitory factor [MIF] and that the myeloid cells had receptors to sense the MIF proteins. This makes them switch their biology and promote, rather than block, tumor growth.”
When the investigators generated tumors from cancer cells that didn’t express MIF, myeloid cells were able to penetrate the tumors, and tumor growth was reduced.
“This means the myeloid cells might have attacked the tumors directly, or might have activated other immune cells, for example, T cells, to attack the tumors,” Guarnerio said.
The investigators believe this information could be used to create novel therapies against soft-tissue sarcoma. A medication designed to stop cancer cells from expressing MIF could be tested in combination with existing therapies, for example, to see if it improves outcomes for patients.
“Recurrent and aggressive soft-tissue sarcoma has proved resistant to our existing therapies,” said Dan Theodorescu, MD, Ph.D., director of Cedars-Sinai Cancer. “Yet interventions aimed at targeting components of the tumor microenvironment, which have shown promise against many solid tumors, have been only marginally tested in soft-tissue sarcoma. This work may pave the way for much more effective interventions.”
Guarnerio plans to pursue these investigations and begin addressing many additional unanswered questions about soft-tissue sarcoma.
“The majority of studies in cancer biology and immunotherapy have been done on carcinoma, the most common type of cancer,” Guarnerio said. “Much work has been done to describe which types of immune cells infiltrate these tumors and how carcinoma cells interact with immune cells, but there is almost no research on sarcomas. We need to continue our investigation so that we understand the roles of many other cells—T cells and B cells, for example—and how all the players work together.”
The research was funded by National Institutes of Health grant numbers K99/R00, CA212200, and R01 CA258265; The Sarcoma Foundation of America grant number 2019 SFA 15-19; and by Cedars-Sinai Cancer.
Reference: “Single-cell RNA-seq of a soft-tissue sarcoma model reveals the critical role of tumor-expressed MIF in shaping macrophage heterogeneity” by Fernando H.G. Tessaro, Emily Y. Ko, Marco De Simone, Roberta Piras, Marina T. Broz, Helen S. Goodridge, Bonnie Balzer, Stephen L. Shiao and Jlenia Guarnerio, 21 June 2022, Cell Reports.
Be the first to comment on "Traitorous Immune Cells: How Tumors Convince Cells To “Go Bad”"